Feeding Problems Are Persistent in Children with Severe Congenital Hyperinsulinism by Indraneel Banerjee et al.
February 2016 | Volume 7 | Article 81
Original research
published: 09 February 2016
doi: 10.3389/fendo.2016.00008
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Radhika Muzumdar, 




Kuopio University Hospital, Finland 
Paul Saenger, 
Albert  Einstein  College  of  Medicine 
of Yeshiva  University and 
SUNY Stony Brook University, USA 
Luigi R. Garibaldi, 
Children’s Hospital of Pittsburgh of 
UPMC, USA
*Correspondence:




This article was submitted to 
Pediatric Endocrinology, 






Banerjee I, Forsythe L, Skae M, 
Avatapalle HB, Rigby L, Bowden LE, 
Craigie R, Padidela R, Ehtisham S, 
Patel L, Cosgrove KE, Dunne MJ and 
Clayton PE (2016) Feeding Problems 
Are Persistent in Children with Severe 
Congenital Hyperinsulinism. 
Front. Endocrinol. 7:8. 
doi: 10.3389/fendo.2016.00008
Feeding Problems are Persistent in 
children with severe congenital 
hyperinsulinism
Indraneel Banerjee1,2* , Lynette Forsythe3 , Mars Skae1 , Hima Bindu Avatapalle1 ,  
Lindsey Rigby1 , Louise E. Bowden1 , Ross Craigie4 , Raja Padidela1 , Sarah Ehtisham1 , 
Leena Patel1 , Karen E. Cosgrove5 , Mark J. Dunne5 and Peter E. Clayton1,2
1 Department of Paediatric Endocrinology, Royal Manchester Children’s Hospital, Manchester, UK, 2 Faculty of Medical and 
Human Sciences, University of Manchester, Manchester, UK, 3 Department of Dietetics and Nutrition, Royal Manchester 
Children’s Hospital, Manchester, UK, 4 Department of Paediatric Surgery, Royal Manchester Children’s Hospital, Manchester, 
UK, 5 Faculty of Life Sciences, University of Manchester, Manchester, UK
Background: Congenital hyperinsulinism (CHI) is a rare but severe disorder of hypo-
glycemia in children, often complicated by brain injury. In CHI, the long-term prevention 
of hypoglycemia is dependent on reliable enteral intake of glucose. However, feeding 
problems (FPs) often impede oral glucose delivery, thereby complicating the manage-
ment of hypoglycemia. FPs have not been systematically characterized in follow-up in a 
cohort with CHI.
aims: We aimed to determine the prevalence, types, and persistence of FPs in a cohort 
of children with CHI and investigate potential causal factors.
Methods: FPs were defined as difficulty with sucking, swallowing, vomiting, and food refusal 
(or a combination) in an observational study in 83 children in a specialized CHI treatment 
center. The prevalence of FPs at diagnosis, 6, and 12 months after diagnosis were noted. 
Genetic mutation status and markers of severity of CHI were tested for association with FPs.
results: A third of children with CHI had FPs (n = 28), of whom 93% required antireflux 
medication and 75% required nasogastric and gastrostomy tube feeding. Sucking and 
swallowing problems were present at diagnosis but absent later. Vomiting was present 
in 54% at 6 months, while food refusal was present in 68% at 6 months and 52% at 
12  months. The age at commencing and stopping nasogastric tube feeding did not 
correlate with FPs frequency at 6 and 12 months. Children with FPs had severe hypo-
glycemia at diagnosis and required glucagon infusion more often [odds ratio (OR) (95% 
confidence intervals) (95% CI) 28.13 (2.6–300.1), p = 0.006] to normalize glucose levels. 
FPs were more frequent in those with diffuse CHI undergoing subtotal pancreatectomy [n 
(%) = 10 (35%) vs. 0 (0%), p < 0.001], in contrast to those with spontaneous resolution [6 
(22%) vs. 32 (58%), p = 0.002]. Those undergoing focal lesionectomy also had reduced 
FPs at 6 months after diagnosis [OR (95% CI) 0.01 (0.0–0.2), R2 = 0.42, p = 0.004]. These 
observations suggest that persistence of hyperinsulinism was associated with FPs.
conclusion: FPs occur in a significant proportion of children with CHI. Severe hyper-
insulinism, rather than nasogastric tube feeding or medications, is the main factor 
associated with FPs.
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inTrODUcTiOn
Congenital hyperinsulinism (CHI) is a rare condition of hypogly-
cemia (reported incidence of severe CHI, 1:30,000–1:50,000) due 
to unregulated and excessive insulin secretion with the potential 
to cause hypoglycemia-related brain injury (1, 2). Children diag-
nosed with CHI can be significantly ill, often requiring prolonged 
periods of hospitalization and intensive medical treatment to 
achieve glycemic stability (3). They are often intolerant of oral 
feeding and may require parenteral nutrition to ensure adequate 
carbohydrate intake to prevent hypoglycemia. Feeding problems 
(FPs) are common in many seriously ill children, but are par-
ticularly frequent and complex in children with CHI, a feature 
that has been recognized in case reports (4, 5), and in a recent 
retrospective observational study (6). However, the prevalence, 
types, extent, and natural history of FPs in follow-up assessments 
have not been described in children with CHI.
Children with CHI often require treatment with oral diazox-
ide, which may be unpleasant to taste. In those who suffer 
adverse effects, or are unresponsive to diazoxide, subcutaneous 
octreotide, a somatostatin analog is used as second-line treat-
ment. Unfortunately, octreotide may cause gastrointestinal 
dysmotility and thereby aggravate FPs. The relative contribution 
of various factors in CHI, including severity of hyperinsulinism, 
iatrogenic adverse effects from medication, and gastrostomy 
feeding, to FPs in CHI are not known. Ensuring adequate feed-
ing tolerance to prevent recurrent hypoglycemia, particularly at 
discharge from hospital, is an essential part of the long-term 
clinical management of CHI. We have therefore investigated 
the nature and duration of FPs and determined possible causal 
factors in a contemporary cohort of CHI patients with the fol-
lowing objectives:
 1. To investigate the prevalence and types of FPs in a cohort of 
children with CHI at diagnosis and in follow-up assessments 
at 6 and 12 months.
 2. To determine factors that could be associated with persistent 
FPs in this cohort.
MaTerials anD MeThODs
FPs were identified at diagnosis in a cohort of children (n = 83) 
with CHI presenting with severe hypoglycemia, consecutively 
over a period of 4  years (2008–2011) to a specialized referral 
treatment center for CHI. The design of the study was observa-
tional over a 12-month period. Diagnosis of CHI was confirmed 
by biochemical investigations as described in a previous study 
(7). Children presenting with significant perinatal asphyxia (i.e., 
those showing clinical features suggestive of hypoxic ischemic 
encephalopathy), surgical bowel anomalies, genetic syndromes, 
and severe neurological abnormalities precluding feeding were 
excluded from recruitment. However, assessment for mild 
neurodevelopmental impairment was not performed. Each child 
with FPs was reviewed at 6 and 12 months after diagnosis. Height 
and weight measurements at these intervals were converted to 
Standard Deviation Scores (SDS) using UK-based normative 
data (8) and were analyzed by non-parametric tests for related 
samples, testing for differences between follow-up visits. All 
children in this cohort had received diazoxide, at least initially, for 
the treatment of hypoglycemia. The standard feeding practice for 
children with CHI over the time period of the study comprised 
of oral milk/food intake, which was increased in 4–6 hourly steps 
as tolerated.
Feeding problems were diagnosed by a dietitian and a speech 
and language therapist within 14 days of diagnosis of CHI and at 
6 and 12 months at routine follow-up clinic visits with multidis-
ciplinary input. In the neonatal period, the assessment of FPs was 
made at the time of establishing oral feeding irrespective of the 
use of intravenous fluids or medications, each feed being at least 
15  ml in volume. FPs were categorized into sucking problems, 
swallowing problems, vomiting, and food refusal. Sucking and 
swallowing problems were diagnosed objectively, if the child did 
not demonstrate adequate oral and pharyngeal reflexes when 
offered a teat, from either a breast or a bottle on consecutive occa-
sions for at least 2 days. If sucking and swallowing problems were 
recurrent, and enteral feeding was deemed clinically important 
to maintain normal blood glucose levels, a nasogastric tube was 
inserted. Children who received this tube were offered oral feed-
ing first with top-up milk feeds if unable to finish the complete 
prescribed volume of milk. The tube was withdrawn if satisfac-
tory oral feeding was established for more than 24 h. The tube was 
also removed in those children receiving a percutaneous-feeding 
gastrostomy.
Vomiting was considered as a FPs by subjective assessment 
of the dietitian, if more than 50% of food contents were brought 
up for at least 50% of feeds offered to the child. In the absence 
of known anatomical causes, such as precipitating and vomiting, 
gastroesophageal reflux was assumed as the etiology. To treat 
vomiting, ranitidine, feed thickener, and domperidone were 
trialed in that order, depending on the response. Food refusal was 
considered as a FPs if the child did not demonstrate an interest to 
engage in oral-feeding maneuvers for milk feeds in the neonatal 
period and liquid and solid foods in later life, in the absence 
of sucking and swallowing problems. Those who did not have 
FPs around the time of diagnosis received routine follow-up as 
clinically indicated. However, as these children did not develop 
FPs in later follow-up, they were not assessed specifically at 6 and 
12 months, unlike the FPs cohort.
Children and families in the FPs cohort required clinical 
psychology support, based on clinical need. However, formal 
psychological assessment was not performed.
All children in the cohort were screened for the presence of 
genetic mutations and received clinical management depending 
on investigation algorithms described previously (7). Focal CHI 
was diagnosed after 18 fluoro Dopa PET-CT scanning and con-
firmed by histology examination after pancreatectomy (3). The 
maximum dose of diazoxide (milligram per kilogram per day) 
and the need for a glucagon infusion were considered as surrogate 
markers for the severity of CHI at diagnosis (9). Carbohydrate 
requirement was not available in children with late presenting 
CHI and therefore was not used as a marker of severity. Children 
TaBle 1 | Differences between groups of children with and without 
feeding problems (FPs): continuous variables are represented as 









Age at presentation (days) 1 (1–365) 1 (1–630) 0.21
Insulin at diagnosis (mU/l) 18.5 (2.5–110.0) 11.2 (2.2–132.0) 0.32
CHI mutations (%) 17 (63.0) 15 (26.8) 0.002*
Maximal dose of diazoxide 
(mg/kg/day)
15.0 (7.0–20.0) 6.1 (4.5–21.0) <0.001*
Octreotide treatment (%) 6 (22) 0 (0) <0.001*
Glucagon infusion (%) 14 (51.9) 5 (8.9) <0.001*
Subtotal pancreatectomy (%) 10 (35) 0 (0) <0.001*
Focal CHI (%) 5 (18.5) 3 (5.4) 0.06
Spontaneous resolution (%) 6 (22.2) 32 (58.2) 0.002*
*p values <0.05 were considered significant.
FigUre 1 | Feeding problems (FPs) in chi patients (n = 28): sucking 
problems, swallowing problems, vomiting, and food refusal at 
diagnosis and at 6 and 12 months in follow-up assessments.
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were considered to have spontaneous resolution if medication 
was discontinued and hypoglycemia resolved spontaneously 
without the need for pancreatic surgery.
Data were analyzed by SPSS 22.0 (©IBM-SPSS), with differ-
ences in frequencies of categorical variables being assessed by 
chi-squared tests and those between continuous variables being 
assessed by Mann–Whitney tests. The association of FPs with 
severity of CHI was determined by a backward-stepwise logistic 
regression model. The study was approved by the local research 
ethics committee.
resUlTs
Prevalence, Types, and Persistence of FPs
In this cohort (n  =  83, 50 males), 28 (34%) children 
(males:females =  21:7) with CHI were identified to have FPs 
at diagnosis. CHI characteristics in those with and without 
FPs have been provided in Table  1. Most CHI children with 
FPs presented early at a median age (range) of 1 (1–365) days, 
but two children presented between 3 and 4  months and 
three children presented between age 7 and 12  months. CHI 
mutations were present in 17 (63%) children. At presenta-
tion, hypoglycemia was severe enough to require intravenous 
glucagon infusion treatment in 14 (52%) children. All children 
were treated with diazoxide, with dosage starting at 5 mg/kg/
day and escalating to a maximum of 15 (7–20) mg/kg/day. In 
the cohort with FPs, 6 (22%) children achieved spontaneous 
resolution of hypoglycemia, while a further 6 (21%) children 
required octreotide for medical treatment of persistent CHI. 
Focal lesions were present in five (19%) children, four of whom 
were treated by focal lesionectomy and one child did not require 
surgery. Subtotal pancreatectomy was performed in 10 (35%) 
children. All families with FPs required clinical psychology 
support at initial presentation and at the 6- and 12-month 
follow-up appointments. Such support was non-structured and 
the interactions were not objectively assessed.
All children with FPs at the time of diagnosis had at least one 
of the following: sucking problems (n = 14, 50%), swallowing 
problems (n = 4, 15%), vomiting (n = 26, 93%), and food refusal 
(n = 15, 54%) (Figure 1). Most children (n = 26, 93%) required 
antireflux treatment with antacids, gelling agents or feed 
thickeners (n = 7, 25%), ranitidine (n = 19, 68%), domperidone 
(n =  25, 89%), omeprazole (n =  13, 46%), and erythromycin 
(n = 4, 14%). Nasogastric tube feeding was commenced in the 
majority of children with FPs (n = 21, 75%) to aid enteral feeding 
to achieve normal glucose status. Gastrostomy tubes (n = 21, 
75%) were inserted after 105 (20; 288) days of nasogastric tube 
feeding to facilitate nutritional intake. Insertion of gastrostomy 
in the child with the longest duration of nasogastric tube feed-
ing (288 days) was delayed because of parental choice. In one 
child, gastrostomy was inserted pre-emptively at the time of 
pancreatic surgery.
Sucking and swallowing problems were present at the time 
of diagnosis but were absent during follow-up. At the 6-month 
assessment, vomiting was still prevalent in a majority (n =  15, 
54%), with subsequent reduction at 12  months (n =  7, 26%) 
(p < 0.001, test for difference across 0, 6, and 12 months). Food 
refusal was present in a significant proportion of children at diag-
nosis, at follow-up at 6 months (n = 19, 68%), and at 12 months 
(n = 14, 52%), indicating long-term persistence of the problem 
(p = 0.14 for difference).
In children with FPs, weight SDS was similar at presentation, 
6 and 12 months in follow-up [median (range) 1.8 (−2.2 to 8.3) 
vs. 1.30 (−2.3 to 4.3) vs. 1.7 (−2.3 to 5.1), p = 0.61 for difference 
between diagnosis and 6 months, p = 0.08 for difference between 
6 and 12 months and p =  0.41 for overall difference], suggest-
ing appropriate nutritional intake despite FPs. Height was also 
TaBle 3 | case illustration.
Patient #19 who had diffuse CHI with compound heterozygous mutations 
in ABCC8, being unresponsive to diazoxide and octreotide, required 
carbohydrate supplementation in feeds to achieve glycemic stability. With 
increasing oral aversion, he became reliant on nasogastric tube feeding. At 
the time of subtotal pancreatectomy, a gastrostomy tube was inserted. In the 
postoperative period, the patient’s FPs worsened with difficulty in maintaining 
glycemic control. The patient achieved improved glycemic stability with a 
second near-total pancreatectomy procedure at the age of 389 days. Since 
then, the patient improved gradually with oral intake and eventually stopped 
relying on gastrostomy feeding at the age of 7 years. This case illustrates the 
relationship between hyperinsulinism and FPs in that delayed resolution of CHI 
is associated with persistence of FPs.
In contrast, patient #17 had inherited a paternal heterozygous mutation 
in ABCC8 and had a focal lesion on PET-CT scanning. A nasogastric tube 
had been inserted shortly at diagnosis to maintain glucose control. In the 
time leading up to focal lesionectomy surgery, the patient developed oral feed 
intolerance. At pancreatic surgery at the age of 90 days, a gastrostomy tube 
was inserted. In the postoperative period, glycemic stability was achieved. 
At the same time, oral feed tolerance returned with no further reliance on 
gastrostomy feeding. Patient #17’s case contrasts to that to patient #19, 
illustrating the possibility that presence and resolution of FPs are associated 
with the persistence and cure of CHI.
TaBle 2 | case illustration.
Patient #14 carrying a GCK mutation had diazoxide-responsive CHI. A 
nasogastric tube had been inserted at birth to support feeding and manage 
hypoglycemia. Although glycemic stability was achieved, the patient continued 
to experience increasing problems with vomiting and oral feed intolerance, 
in spite of antireflux medication and variations in milk formulations, thereby 
requiring persistent nasogastric tube feeding as a reliable source of nutritional 
intake. Due to the reliance on nasogastric tube feeding, a gastrostomy tube 
was inserted at the age of 157 days. The patient required regular speech 
and language therapy and dietetic input and at the age of 2.5 years gradually 
improved oral intake, although occasionally reliant on gastrostomy feeding. 
This case illustrates the practical difficulty with weaning nasogastric tube 
feeding in some children with CHI complicated by FPs.
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similar with no difference observed between 6 and 12 months [0.9 
(−1.0 to 3.7) vs. 0.6 (−1.0 to 3.5), p = 0.32].
risk Factors and associations with FPs
In contrast to the group of children without FPs, those with 
FPs required higher maximal diazoxide dose and had a higher 
frequency of glucagon infusions, indicating greater severity of 
disease (Table 1). Diazoxide itself was not the cause for FPs; it 
was evident by the observation that FPs was persistent in those 
in whom diazoxide was discontinued (n = 9, 53%). Further, the 
maximum dose of diazoxide was not correlated with the presence 
of food refusal either at diagnosis (p = 0.98), 6 months (p = 0.71), 
or at 12 months (p = 0.22), indicating the absence of a diazoxide 
dose-dependent effect on the prevalence of FPs, either in the 
short- or long term. Therefore, the association of FPs and diazox-
ide implies an indirect correlation of FPs with the severity of CHI. 
Likewise, FPs predated the introduction of octreotide, which was 
commenced following unresponsiveness or adverse events on 
diazoxide. Therefore, it is unlikely that FPs were causally related 
to octreotide. This is further supported by the observation that 
FPs persisted after octreotide was discontinued.
The group with FPs also had a higher frequency of genetic 
mutations, a higher frequency of children requiring medical 
treatment with octreotide, and a higher proportion of children 
requiring pancreatectomy, indicating more severe CHI. Not 
surprisingly, few children in this group achieved spontaneous 
resolution.
Markers suggestive of greater severity of CHI disease were 
entered into a backward logistic regression model (R2 =  0.50, 
p < 0.001), using and adjusting for variables in Table 1 (with the 
addition of gender, gestation, and birth weight). Diazoxide and 
octreotide were excluded from the regression as FPs predated 
and postdated the start and stop times for treatment to bear tem-
poral association. FPs were most likely to be associated with the 
presence of KATP channel gene mutations as expected [odds ratio, 
OR (95% confidence intervals, CI) 6.16 (1.1–36.3), p =  0.04] 
and the use of glucagon infusion [OR (CI) 28.13 (2.6–300.1), 
p = 0.006]. In those with FPs, glucagon was administered in 6 
(16%) children who achieved spontaneous resolution in contrast 
to 13 (30%) children who had persistent disease (p =  0.19 for 
difference). Therefore, cumulative dose of glucagon was not cor-
related with FPs.
In the group with FPs, food refusal at diagnosis was not cor-
related with birth weight, gestation, age at presentation, KATP 
channel gene mutations, diagnosis of focal CHI, requirement of 
glucagon infusion, or the achievement of spontaneous resolution. 
Food refusal at 6 months (R2 = 0.54 for model, p = 0.001) was 
less likely in those who achieved spontaneous resolution [OR 
0.1 (0.1–0.8), p = 0.04] and had a focal lesion [OR 0.1 (0.1–0.2), 
p =  0.004], the latter retaining significance at 12  months in a 
similar model [OR 0.1 (0.0–0.7), R2 = 0.42, p = 0.002].
To test the possibility that nasogastric tube feeding was detri-
mental to oral feeding, age at commencing and stopping nasogas-
tric tube feeding was tested for correlation with the frequency of 
FPs at 6 and 12 months. There was no difference in FPs frequency 
for age at commencing or age at stopping nasogastric tube feed-
ing at 6  months (p =  0.57, p =  0.28) or 12  months (p =  0.33, 
p = 0.30), respectively. Therefore, the introduction and persistence 
of nasogastric tube feeding were not directly implicated in FPs. 
The presence of gastrostomy feeding was also tested against food 
refusal at 12 months, but there was no association (p = 0.24). This 
suggests that late, persistent food refusal was not related to gastros-
tomy insertion after diagnosis. The requirement for persistence of 
nasogastric tube feeding has been supported by two case illustra-
tions in Tables 2 and 3.
DiscUssiOn
We have described the prevalence and persistence of FPs in a 
significant proportion of children with CHI. Vomiting and food 
refusal are major problems, which may occur at diagnosis but 
are more prominent later in the course of the disease. Analysis 
of factors characterizing CHI at diagnosis and review at 6 and 
12 months suggests that CHI disease severity may play a causal 
role. The use of medications, nasogastric tube feeding, and gas-
trostomy devices are unlikely to be individually responsible for 
causing FPs.
There have been no comparative studies reporting on the 
prevalence of FPs, although a recent study noted that 19 (45%) out 
of 42 patients with severe CHI, of whom 79% required subtotal 
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pancreatectomy over a 15-year period, had food aversion (6). 
While FPs is well recognized in CHI, causal and associated factors 
have not been analyzed. It is commonly assumed that FPs may be 
secondary to treatment, such as diazoxide (metallic after taste) 
and octreotide (gut dysmotility), or aggravated by nasogastric 
tube feeding and subsequent lack of oral exposure. However, in 
our study, we have shown that FPs is less likely to be influenced 
by medication (diazoxide and octreotide) and the introduction 
of nasogastric tube feeding than by the severity of illness. The 
correlation of glucagon administration with FPs is likely to reflect 
severity of CHI, although the possibility of glucagon directly 
suppressing feeding behavior through its effects on the central 
nervous system cannot be excluded (10). The observation that 
glucagon treatment was associated with FPs regardless of cumu-
lative dose argues against a dose–response effect and hence less 
likely a treatment side effect. Further evidence for the link of FPs 
with severity comes with the observation of improvement in FPs 
with resolution of CHI, as in those with spontaneous resolution 
and those in the postfocal lesionectomy period. However, the 
study did not address the temporal correlation between resolu-
tion of CHI and the resolution of FPs, which could be investigated 
by longitudinal follow-up studies examining the natural history 
of CHI. Nonetheless, no child with normal feeding developed 
late onset FPs, reinforcing the correlation of severity of CHI at 
presentation and FPs.
All children who required nasogastric tube feeding for per-
sistent FPs had gastrostomy insertion. Therefore, it appears from 
our cohort that gastrostomy feeding is more likely in children 
who have persistent severe FPs, and that early gastrostomy 
insertion may be necessary in the clinical management of CHI 
complicated by FPs.
The prevalence of KATP channel gene mutations, diazoxide 
responsiveness, and rates for surgery is broadly commensurate 
with other CHI cohorts (7). Although our cohort of 28 children 
with FPs is relatively small, they have been well characterized, 
both from a CHI perspective and from a feeding/dietetic perspec-
tive, with formal evaluation at 6 and 12 months after diagnosis. 
Further, we have recruited a relatively large group without FPs 
to enhance the strength of associations suggesting severity of 
hyperinsulinism as a probable causal agent.
We did not specifically evaluate the neurological status of 
patients in this cohort, in contrast to a previous study (6), but 
had excluded patients with severe neurological abnormalities 
likely to adversely influence feeding. It is possible that significant 
neurological adverse outcomes secondary to neuroglycopenia 
may have caused FPs in some individuals. However, at 12 months 
postdiagnosis, no child recruited to this study had evidence of 
neurologic injury severe enough to cause FPs. Although not 
assessed, children with mild neurodevelopmental impairment 
were likely to be present both in those with and without FPs, 
suggesting an unlikely role for brain damage as a cause for FPs in 
our short-term assessment. Nonetheless, it would be important to 
assess for mild neurodevelopmental impairment in the long-term 
follow-up of children with FPs.
While examining for risk factors influencing FPs, we have not 
assessed if hyperglycemia may have played a part in the causa-
tion of FPs. It is possible that FPs occurred in this cohort due to 
inadvertent hyperglycemia from overenthusiastic glucose supple-
mentation in some individuals, although there is no evidence that 
hyperglycemia in neonates causes FPs. In older children with type 
1 diabetes, vomiting or food refusal is not commonly described, 
although gastroparesis can occur in 10% individuals (11). While 
electrogastrography studies in type 1 diabetes children suggest 
early onset of dysmotility problems due to acute hyperglycemia, 
there is no strong evidence for hyperglycemia to cause food 
refusal behavior in younger children with CHI.
All children and families who had FPs required clinical 
psychology support as part of routine clinical management. The 
psychology support addressed FPs in addition to other issues 
related to CHI, i.e., stress related to disease, long duration of 
treatment, and hospital stay. However, the study did not quantify 
the psychological impact on the family through inventories and 
questionnaires. The design did not incorporate strategies to 
investigate and ameliorate psychological concerns specifically 
arising from FPs in the context of CHI. However, considering that 
children with FPs required psychological support, future studies 
should explore FPs-specific psychological outcomes.
In our study, we are aware that the strength of association 
of FPs with factors marking severity in subgroup analyses may 
be weak. Nonetheless, the reduction of food refusal prevalence 
after spontaneous resolution of CHI and focal CHI surgery is 
compelling evidence to suggest a role for persistent hyperinsu-
linism in the pathogenesis of FPs. It is recognized that insulin 
can be an appetite stimulant in normal individuals, mediated 
by hypoglycemia. However, it has also been recognized that 
gastric motility can be reduced in adult healthy volunteers by 
the introduction of relatively large doses of insulin (12). Recent 
work suggests that insulin may also reduce appetite and feeding 
through signaling mechanisms in the brain (13), with further 
evidence that insulin may suppress appetite by anorexigenic 
mechanisms in the hypothalamus, either activating mammalian 
target of rapamycin 1 (mTORC1) (14) or suppressing ghrelin-
induced calcium signaling in neuropeptide Y neurons (15). It is 
possible that severe hyperinsulinism in children with CHI may 
play a causal role in the pathogenesis of persistent FPs, consistent 
with observations that insulin signaling in the brain may regulate 
feeding behavior in animals (16).
cOnclUsiOn
FPs can occur in children with CHI and may persist until 1 year 
after diagnosis, particularly as food refusal. The cause for FPs is 
not clear but severity of CHI is a consistent association. Further 
studies are required to evaluate the longer term natural history 
of FPs and to investigate how insulin alters feeding behavior and 
whether prompt treatment of hyperinsulinism may prevent FPs 
in children with CHI.
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